Management of bleeding events and invasive procedures in patients with haemophilia A without inhibitors treated with emicizumab

Management of bleeding events and invasive procedures in patients with haemophilia A without inhibitors treated with emicizumab

INTRODUCTION Emicizumab (Hemlibra®, Hoffmann-La Roche, Switzerland) is now available for haemophilia A patients with or without factor VIII inhibitors. Management of bleeding events and replacement therapy for invasive procedures have to be adapted. OBJECTIVE...

Full description

Bibliographic Details
Main Authors: Pierre Fontana, Lorenzo Alberio, Manuela Albisetti, Anne Angelillo-Scherrer, Lars M. Asmis, Alessandro Casini, Bernhard Gerber, Lukas Graf, Inga Hegemann, Wolfgang Korte, Maria Martinez, Jan-Dirk Studt, Dimitrios A. Tsakiris, Walter A. Wuillemin, Johanna A. Kremer Hovinga
Format: Article
Language:English
Published: SMW supporting association (Trägerverein Swiss Medical Weekly SMW) 2020-12-01
Series:Swiss Medical Weekly
Subjects:
emicizumab
bleeds
invasive procedures
Guidelines
Online Access:https://www.smw.ch/index.php/smw/article/view/2933

Internet

https://www.smw.ch/index.php/smw/article/view/2933

Similar Items